Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIRT6-aav.017 is a recombinant adeno-associated virus (rAAV) gene therapy candidate developed by SirtLab for the treatment of neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The therapeutic approach involves the delivery of the SIRT6 gene to the central nervous system to achieve sustained expression of the SIRT6 protein. SIRT6 is a member of the sirtuin family of NAD+-dependent deacetylases that plays a critical role in DNA repair, genomic stability, and metabolic homeostasis. By enhancing SIRT6 levels, the therapy aims to provide neuroprotective effects and counteract the cellular aging processes associated with neurodegeneration. SIRT6-aav.017 is currently in preclinical development, having demonstrated proof-of-concept in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SIRT6-aav.017.